Several other brokerages have also weighed in on FRE. Goldman Sachs Group set a €78.00 ($96.30) price objective on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Tuesday, October 31st. Barclays set a €81.00 ($100.00) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, February 2nd. Warburg Research set a €80.00 ($98.77) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, December 21st. Bank of America set a €75.00 ($92.59) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Monday, November 6th. Finally, Kepler Capital Markets set a €63.00 ($77.78) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of €77.89 ($96.16).
Shares of Fresenius SE & Co KGaA (FRA:FRE) opened at €67.80 ($83.70) on Tuesday. The firm has a market capitalization of $37,860.00 and a price-to-earnings ratio of 21.59. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($74.27) and a twelve month high of €80.00 ($98.77).
TRADEMARK VIOLATION WARNING: “Fresenius SE & Co KGaA (FRE) PT Set at €85.00 by Commerzbank” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3227485/fresenius-se-co-kgaa-fre-pt-set-at-85-00-by-commerzbank.html.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.